Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$69 Mln
P/E Ratio
--
P/B Ratio
19.72
Industry P/E
--
Debt to Equity
10.09
ROE
-3.91 %
ROCE
-92.29 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-171.22 Mln
EBITDA
$-220.96 Mln
Net Profit
$-193.70 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Rani Therapeutics Holdings Inc (RANI)
| -16.42 | -26.13 | -22.64 | -82.88 | -55.64 | -- | -- |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Rani Therapeutics Holdings Inc (RANI)
| -58.44 | -43.73 | -63.91 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.41 | 9,808.03 | 20.22 | 23.13 | |
| 299.04 | 8,956.09 | 22.08 | 58.42 | |
| 26.78 | 9,559.25 | -- | -28.77 | |
| 104.84 | 10,030.35 | 30.81 | 14.16 |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a... drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. Address: 2051 Ringwood Avenue, San Jose, CA, United States, 95131 Read more
Executive Chairman
Mr. Mir A. Imran
Executive Chairman
Mr. Mir A. Imran
Headquarters
San Jose, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Rani Therapeutics Holdings Inc (RANI) stood at $ 37 Mln as on 31-Dec-24
The share price of Rani Therapeutics Holdings Inc (RANI) is $1.15 (NASDAQ) as of 24-Apr-2025 11:32 EDT. Rani Therapeutics Holdings Inc (RANI) has given a return of -55.64% in the last 3 years.
Rani Therapeutics Holdings Inc (RANI) has a market capitalisation of $ 69 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Rani Therapeutics Holdings Inc (RANI) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Rani Therapeutics Holdings Inc (RANI) and enter the required number of quantities and click on buy to purchase the shares of Rani Therapeutics Holdings Inc (RANI).
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. Address: 2051 Ringwood Avenue, San Jose, CA, United States, 95131
The CEO & director of Mr. Mir A. Imran. is Rani Therapeutics Holdings Inc (RANI), and CFO & Sr. VP is Mr. Mir A. Imran.
There is no promoter pledging in Rani Therapeutics Holdings Inc (RANI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Rani Therapeutics Holdings Inc (RANI) | Ratios |
|---|---|
|
Return on equity(%)
|
-404.07
|
|
Operating margin(%)
|
-5014.69
|
|
Net Margin(%)
|
-2920.04
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Rani Therapeutics Holdings Inc (RANI) was $0 Mln.
$-0.01
(
